Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (GB:0A4W)
LSE:0A4W
RESEARCH TOOLSreports
Holding GB:0A4W?
Track your performance easily
0A4W Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.47 - $32.51
Previous Close$14.48
Volume558.00
Average Volume (3M)995.00
Market Cap
$2.40B
Enterprise Value$1.87B
Total Cash (Recent Filing)$572.47M
Total Debt (Recent Filing)$47.19M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Oct 31, 2024EPS Estimate
$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding165,876,052
10 Day Avg. Volume750
30 Day Avg. Volume995
Standard Deviation0.16
R-Squared0.00018
Alpha-0.00630
Financial Highlights & Ratios
Price to Book (P/B)4.80
Price to Sales (P/S)2.69
Price to Cash Flow (P/CF)24.00
P/FCF Ratio24.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.10
Enterprise Value/Gross Profit2.74
Enterprise Value/Ebitda37.10
Forecast
1Y Price Target
$25.59Price Target Upside76.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
ACADIA Pharmaceuticals News
PremiumCompany Announcements
ACADIA Pharmaceuticals Welcomes New CEO, Unveils Compensation Plan
Bulls Say, Bears Say
Bulls Say
Management And LeadershipCatherine Owen Adams has experience leading global commercial operations.
New Product PipelineCobenfy and ACP-204 would be first drugs approved for Alzheimer's disease psychosis.
Regulatory ApprovalFDA may revisit the warning on Nuplazid's label, which could drive incremental but unanticipated growth among Parkinson's patients.
Bears Say
Investor SentimentShares remain under pressure on negative sentiment from label expansion setbacks and challenging patient dynamics.
Revenue GuidanceManagement lowered 2024 total revenue guidance to $930 — 980M mainly due to a decrease in its outlook for Daybue.
Sales PerformanceDaybue sales were disappointing, leading to lower 2024 Daybue sales guidance and, consequently, overall 2024 revenue guidance.
---
Options Prices
Currently, No data available
---
Ownership Overview
24.14% Insiders
15.30% Mutual Funds
0.02% Other Institutional Investors
43.72% Public Companies and
Individual Investors
0A4W FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest share price was $14.47 and its highest was $32.51 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 20 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Aug 06, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of $0.178 by $0.022.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is $0.14.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 165,876,050 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.2 in its last earnings report, beating expectations of $0.178. Following the earnings report the stock price went down -18.032%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 697M.
---
ACADIA Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.59 (76.75% Upside)
$25.59 (76.75% Upside)
Blogger Sentiment
Bullish
GB:0A4W Sentiment 83%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.88%
12-Months-Change
Fundamentals
Return on Equity
6.70%
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
0A4W Company Deck
---
0A4W Earnings Call
Q2 2024
0:00 / 0:00
---
0A4W Stock 12 Month Forecast
Average Price Target
$25.59
▲(76.75% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alkermes
―
Axsome Therapeutics
―
SAGE Therapeutics
―
Ironwood Pharma
―
Best Analysts Covering 0A4W
1 Year
1 Year Success Rate
13/24 ratings generated profit
1 Year Average Return
+5.16%
assigned a buy rating 2 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +5.16% per trade.
---